Medical sign

Alabama State University Selects Draganfly to Provide the Safe School Solution™ Utilizing it’s Vital Intelligence Technology

Retrieved on: 
Tuesday, September 1, 2020

The Smart Thermal Temperature Assessment Stations, Vital Sign Assessment Stations and Social Distancing units are North American made and owned.

Key Points: 
  • The Smart Thermal Temperature Assessment Stations, Vital Sign Assessment Stations and Social Distancing units are North American made and owned.
  • Data provided back to Alabama State University will include the number of individuals screened, number of elevated temperatures and potential cases with elevated vital signs detected and the time it took for each screening.
  • The data will also provide real-time data on the overall health of Alabama State Universitys community in relation to scans.
  • We are excited that Alabama State University has chosen Draganfly to implement our Vital Intelligence technology on their campus, said Cameron Chell, CEO of Draganfly.

Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project

Retrieved on: 
Monday, July 20, 2020

The selected study and development project is as follows:

Key Points: 
  • The selected study and development project is as follows:
    Study of the monitoring system for COVID-19 patient on the home/hotel recuperation.
  • Duration of study and development: from grant delivery decision date during 2020 until March 31, 2021 (1 year).
  • Accommodation care facilities were insufficient such that among patients testing positive, those with mild symptoms or without symptoms had to share accommodations.
  • This function is equipped with AI to measure vital signs including SpO2, respiratory rate, and blood pressure using a smartphone camera.

Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis

Retrieved on: 
Saturday, June 6, 2020

"The updated PIONEER trial data showed that patients treated with avapritinib had clinically meaningful reductions in mediator symptoms, patient-reported quality of life and mast cell burden across multiple measures.

Key Points: 
  • "The updated PIONEER trial data showed that patients treated with avapritinib had clinically meaningful reductions in mediator symptoms, patient-reported quality of life and mast cell burden across multiple measures.
  • With further evidence that these reductions deepen over time, avapritinib has the potential to provide important clinical benefits to patients with this debilitating disease."
  • "Avapritinib was specifically designed to potently target the underlying disease driver of systemic mastocytosis and has the potential to fundamentally change the treatment of this disease."
  • Updated data on disease symptoms through 24 weeks and new skin assessment results were reported in the EAACI presentation.

PMD Healthcare Is Now RemetricHealth, Helping Reimagine Healthcare Through Remote Monitoring and Telehealth

Retrieved on: 
Tuesday, June 2, 2020

In 2010, RemetricHealth, then known as PMD Healthcare, developed the first-ever patented, FDA-approved at-home personal spirometer, Spiro PD, which measures lung function.

Key Points: 
  • In 2010, RemetricHealth, then known as PMD Healthcare, developed the first-ever patented, FDA-approved at-home personal spirometer, Spiro PD, which measures lung function.
  • The kits also are beneficial for chronic care management for conditions including CHF, hypertension, COPD and diabetes, as well as COVID-19 symptom monitoring.
  • Our work in remote patient monitoring and telehealth is more relevant to patients and their circumstances than it has ever been."
  • Physicians who work with RemetricHealth to offer telehealth and remote patient monitoring can help patients outside the office and are earning significant reimbursements.

BioIQ Launches Telehealth Enabled At-Home Saliva Test Kit for COVID-19 with P23 Labs

Retrieved on: 
Tuesday, June 2, 2020

The test sample collection kit includes an easy-to-use, self-administered saliva collection kit and virtual telehealth guidance, along with access to a health technology platform to support digital symptom and exposure assessment, contact tracing, and follow-up care navigation.

Key Points: 
  • The test sample collection kit includes an easy-to-use, self-administered saliva collection kit and virtual telehealth guidance, along with access to a health technology platform to support digital symptom and exposure assessment, contact tracing, and follow-up care navigation.
  • "The combination of easy home saliva collection along with integrated telehealth presents a significant step forward for the diagnostic testing of COVID-19," said BioIQ CEO Justin Bellante.
  • "P23 Labs is enthusiastic to work with BioIQ to increase COVID-related testing access in the US," said P23 Labs Sr. Regulatory Officer Mary Smith.
  • "Our at-home kit elevates saliva-based COVID-19 testing standards with a highly accurate test that marries convenience with remote clinician oversight.

InventHelp Inventor Develops Accurate Way to Access Heart & Lung Conditions (BTM-2721)

Retrieved on: 
Tuesday, April 21, 2020

PITTSBURGH, April 21, 2020 /PRNewswire/ -- "I'm a nurse practitioner in quest of creating a more accurate and timely way of completing lung and heart assessments," said an inventor, from Freeland, Md., "so I invented the A.S.

Key Points: 
  • PITTSBURGH, April 21, 2020 /PRNewswire/ -- "I'm a nurse practitioner in quest of creating a more accurate and timely way of completing lung and heart assessments," said an inventor, from Freeland, Md., "so I invented the A.S.
  • The patent pending invention is an improved stethoscope designed to assist healthcare professionals in accurate and timely assessments of lung and heart sounds.
  • As a result, it would improve assessments, guide accurate diagnoses, expedite care and help to save lives.
  • 18-BTM-2721, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

IRADIMED CORPORATION to Hold 2020 First Quarter Financial Results Conference Call on April 30th

Retrieved on: 
Thursday, April 16, 2020

WINTER SPRINGS, Fla., April 16, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 first quarter financial results before the market opens on Thursday, April30th.

Key Points: 
  • WINTER SPRINGS, Fla., April 16, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 first quarter financial results before the market opens on Thursday, April30th.
  • iRadimed management will host a conference call the same day beginning at 11:00a.m.
  • Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 6542729.
  • The iRadimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

IRADIMED CORPORATION to Hold 2019 Fourth Quarter Financial Results Conference Call on February 6th

Retrieved on: 
Wednesday, January 22, 2020

WINTER SPRINGS, Fla., Jan. 22, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 fourth quarter financial results before the market opens on Thursday, February6th.

Key Points: 
  • WINTER SPRINGS, Fla., Jan. 22, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 fourth quarter financial results before the market opens on Thursday, February6th.
  • IRADIMED management will host a conference call the same day beginning at 11:00a.m.
  • Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 7783873.
  • The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

Biomerica Announces Second Quarter Financial Results; Sales Up 6.4% for the Quarter

Retrieved on: 
Wednesday, January 15, 2020

Net sales were $2,790,823 for the six months ended November 30, 2019 compared to $2,773,661 for the same period last fiscal year.

Key Points: 
  • Net sales were $2,790,823 for the six months ended November 30, 2019 compared to $2,773,661 for the same period last fiscal year.
  • We are excited about progress were making in moving toward completion of the clinical trials for our InFoods IBS product and H. pylori diagnostic product.
  • The Biomerica InFoods IBS product is designed to allow physicians to identify patient specific foods (e.g.
  • The Company is under no obligation to update any forward-looking statements after the date of this release.

AI System Accurately Detects Key Findings in Chest X-Rays of Pneumonia Patients Within 10 Seconds; Study Finds Promise of Faster Treatment

Retrieved on: 
Tuesday, October 1, 2019

The study found that those ultra-quick findings will enable physicians reading X-rays to accurately confirm a pneumonia diagnosis significantly faster than current clinical practice, enabling treatment to start sooner, which is vital for severely ill patients whore suffering from pneumonia.

Key Points: 
  • The study found that those ultra-quick findings will enable physicians reading X-rays to accurately confirm a pneumonia diagnosis significantly faster than current clinical practice, enabling treatment to start sooner, which is vital for severely ill patients whore suffering from pneumonia.
  • Findings from the collaborative study were presented at the European Respiratory Societys International Congress 2019, held in Madrid, Spain, this week.
  • Researchers found the CheXpert system identified key findings in X-rays very accurately with high agreement to a consensus of three radiologists in about 10 seconds, which significantly outperforms current clinical practice.
  • For the study, Intermountain radiologists categorized chest images from 461 Intermountain patients as being likely, likely-uncertain, unlikely-uncertain, or unlikely to have pneumonia.